|
刘祥瑞，浙江大学副教授，浙江大学求是学者，博士生导师。研究方向主要包括抗肿瘤分子药剂、肿瘤免疫治疗、基因输送、药物递送材料、药用高分子等。其作为负责人承担多项科研项目，目前是DARU Journal of Pharmaceutical Sciences编委，Biomaterials, Theranostics, Journal of ControlledRelease, Molecular Pharmaceutics, International Journal of Pharmaceutics 等杂志审稿人，并且是中国营养学会肿瘤营养管理分会委员，中国抗癌协会纳米肿瘤专委会青委会委员，浙江省药学会生物制药专业委员会青委会委员，浙江省发明协会靶向治疗专业委员会副秘书长。因论坛不能发表URL链接，刘祥瑞老师的个人主页以及联系方式可在附件中查看。
刘祥瑞 单位：化学工程与生物工程学院 职称：副教授 个人简介 2001-2005年 北京大学药学院 药学学士 2005-2007年 北京大学药学院 药剂学硕士 2008-2011年 英国诺丁汉大学药学院 药学博士 2011-2013年 英国医学研究理事会分子生物学实验室 （MRC LMB） / 剑桥大学 博士后 2013年加入浙江大学化学工程与生物工程学院 生物纳米工程中心 副教授 求是青年学者 博士生导师 DARU Journal of Pharmaceutical Sciences编委 Journal of Controlled Release, MolecularPharmaceutics, International Journal of Pharmaceutics 等杂志审稿人 美国癌症学会、中国化学会、中国营养学会会员、浙江省药学会生物制药专业委员会青委会委员 工作研究领域 纳米药物,分子药剂学,非病毒载体基因输送,肿瘤微环境,口服膳食补充剂。 联系方式 发表论文 Zhangdan Huang, Xuanrong Sun, Xiangrui Liu*; Youqing Shen, Kai Wang*Macrophagesas an active tumour-targeting carrier of SN38-nanoparticles for cancer therapyJournal of drug targeting (Epub 2017 Dec 27) Bingxiang Zhao, Sufang Gu, YongDu, Minjie Shen, Xiangrui Liu*, Youqing Shen. Solidlipid nanoparticles as carriers for oral delivery of hydroxysafflor yellowA. International journal of pharmaceutics 535 (2018) 164–171 Quan Zhou, Yongcun Zhou, XiangruiLiu*, Youqing Shen*. GDC-0449 improves theantitumor activity of nano-doxorubicin in pancreatic cancer in afibroblast-enriched microenvironment Scientific Reports 2017| 7:13379 | DOI:10.1038/s41598-017-13869-0 Liying Wang, Xiangrui Liu*,etc. Terminating the criminal collaboration inpancreatic cancer:Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drugresistance. Biomaterials 144 (2017) 105-118 Liying Wang, Quan Zhou, XiangruiLiu*, etc. Enhanced anti-tumor efficacy by co-delivery ofGDC-0449 with size-tunable polymeric SN38 nanoparticles in pancreaticcancer Journal ofControlled Release, 259, 2017 e87-88 Zhuxian Zhou#, Xiangrui Liu#,etc (co-first author). Nonviral Cancer Gene Therapy: Delivery Cascadeand Vector Nanoproperty Integration. Advanced Drug DeliveryReviews （115）2017 115-154 Xuefei Zhou, Xiangrui Liu*,etc. Jumping the nuclear envelope barrier: Improvingpolyplex-mediated gene transfection efficiency by a selective CDK1 inhibitorRO-3306. Journal of Controlled Release 234 (2016) 90–97 Xiangrui Liu, Rainer Wilcken, etc. Small-molecule induced reactivationof mutant p53 in cancer cells. Nucleic Acid Research 2013Jul 1;41(12):6034-44 Xiangrui Liu, Shenhua Shi, etc. CDKI-71, anovel CDK9 inhibitor, is preferentially cytototoxic to cancer cellscompared to flavopiridol. Int J Cancer. 2012 Mar1;130(5):1216-26 Xiangrui Liu, Frankie Lam, etc. In vitroantitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Investigationalnew drugs 2012 Jun;30(3):889-97 Xiangrui Liu, Jiabei Sun, etc. Pharmacokinetics,tissue distribution and anti-tumour efficacy of paclitaxel delivered bypolyvinylpyrrolidone solid dispersion. Journalof pharmacy and Pharmacology.2012 Jun;64(6):775-82 Xiang-Rui Liu, Ke-Chun Wu, etc. In Vitro andin Vivo Studies on Plasma to Blood Ratio of Paclitaxel in Human, Rabbit and RatBlood Fractions. Bio. Pharm. Bull 2008 31(6)/1215-1220 Xiangrui Liu, Shenhua Shi, etc. Cellularmechanism of a novel CDK9 inhibitor CDKI-71. EJC supplements 20108(5)/54/1 Xiangrui Liu, Jiabei Sun, etc. Pharmacokinetics,Biodistribution, Acute Toxicity and In Vivo Anti-tumour Efficacy of Paclitaxel Solid Dispersion Journal of pharmacyand Pharmacology.2010 Oct; Vol. 62 (10) 1234-35 Rainer Wilcken, Xiangrui Liu,etc. Halogen-enriched fragment libraries asleads for drug rescue of mutant p53. J Am ChemSoc. 2012 Apr 18;134(15):6810-8 Hao Shao, Shenhua Shi, Shiliang Huang,Alison Hole, Abdullahi Y Abbas, Sonja Baumli, Xiangrui Liu,Frankie Lam, David W Foley, Peter M Fischer, Martin Noble, Jane A Endicott,Chris Pepper, Shudong Wang Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, x-ray crystalstructure, SAR and anti-cancer activities. Journal of MedicinalChemistry 2013/01 Pawel M Lukasik, Sherifa Elabar, FrankieLam, Hao Shao, Xiangrui Liu, Abdullah Y Abbas, ShudongWang. Synthesisand biological evaluation of imidazo [4, 5-b] pyridine and4-heteroaryl-pyrimidine derivatives as anti-cancer agents Europeanjournal of medicinal chemistry 2012
| 
发表于 2018-5-24 17:22:45
QQ好友和群
QQ空间
腾讯微博
腾讯朋友
收藏
转播
分享
淘帖
